Skip to main content

Advertisement

SpringerLink
Log in

Iron metabolism and drug resistance in cancer

  • Published:
BioMetals Aims and scope Submit manuscript

Abstract

Iron is an essential inorganic element for various cellular events. It is directly associated with cell proliferation and growth; therefore, it is expected that iron metabolism is altered in tumor cells which usually have rapid growth rates. The studies on iron metabolism of tumor cells have shown that tumor cells necessitated higher concentrations of iron and the genes of iron uptake proteins were highly over-expressed. However, there are limited number of studies on overall iron metabolism in drug-resistant tumor cells. In this article, we evaluated the studies reporting the relationship between drug resistance and iron metabolism and the utilization of this knowledge for the reversal of drug resistance. Also, the studies on iron-related cell death mechanism, ferroptosis, and its relation to drug resistance were reviewed. We focus on the importance of iron metabolism in drug-resistant cancer cells and how alterations in iron metabolism participate in drug-resistant phenotype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Adapted from Torti and Torti (2013a, b)

Fig. 2

Similar content being viewed by others

References

  • Alkhateeb AA, Connor JR (2010) Nuclear ferritin: a new role for ferritin in cell biology. Biochem Biophys Acta 1800:793–797. doi:10.1016/j.bbagen.2010.03.017

    Article  CAS  PubMed  Google Scholar 

  • Arun R, Dhivya S, Abraham SK, Premkumar K (2016) Low-dose chemotherapeutic drugs induce reactive oxygen species and initiate apoptosis-mediated genomic instability. Toxicol Res 5:547–556. doi:10.1039/C5TX00391A

    Article  CAS  Google Scholar 

  • Barabas K, Faulk WP (1993) Transferrin receptors associate with drug resistance in cancer cells. Biochem Biophys Res Commun 197:702–708

    Article  CAS  PubMed  Google Scholar 

  • Broxmeyer HE, Cooper S, Levi S, Arosio P (1991) Mutated recombinant human heavy-chain ferritins and myelosuppression in vitro and in vivo: a link between ferritin ferroxidase activity and biological function. Proc Natl Acad Sci USA 88:770–774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Campanella A, Santambrogio P, Fontana F, Frenquelli M, Cenci S, Marcatti M et al (2013) Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica 98:971–979. doi:10.3324/haematol.2012.074872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Canzoneri JC, Oyelere AK (2008) Interaction of anthracyclines with iron responsive element mRNAs. Nucleic Acids Res 36:6825–6834. doi:10.1093/nar/gkn774

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cao JY, Dixon SJ (2016) Mechanisms of ferroptosis. Cell Mol Life Sci 73:2195–2209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chauhan D, Hideshima T, Anderson KC (2005) Proteasome inhibition in multiple myeloma: therapeutic Implication. Annu Rev Pharmacol Toxicol 45:465–476

    Article  CAS  PubMed  Google Scholar 

  • Chekhun VF, Lukyanova NY, Burlaka AP, Bezdenezhnykh NA, Shpyleva SI, Tryndyak VP et al (2013) Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int J Oncol 43:1481–1486. doi:10.3892/ijo.2013.2063

    Article  CAS  PubMed  Google Scholar 

  • Chekhun VF, Lozovska YV, Burlaka AP, Lukyanova NY, Todor IN, Naleskina LA (2014) Peculiarities of antioxidant system and iron metabolism in organism during development of tumor resistance to cisplatin. Exp Oncol 36:196–201

    CAS  PubMed  Google Scholar 

  • Chekhun VF, Lukyanova NY, Borikun TV, Zadvornyi TV, Mokhir A (2017) Artemisinin modulating effect on human breast cancer cell lines with different sensitivity to cytostatics. Exp Oncol 39:25–29

    CAS  PubMed  Google Scholar 

  • Chen L, Li X, Liu L, Yu B, Xue Y, Liu Y (2015) Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function. Oncol Rep 33:1465–1474

    Article  CAS  PubMed  Google Scholar 

  • Chitambar CR (2004) Gallium nitrate for the treatment of non-Hodgkin’s lymphoma. Drugs 13:531–541

    CAS  Google Scholar 

  • Chitambar CR, Seligman PA (1986) Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. J Clin Investig 78:1538–1546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chitambar CR, Wereley JP (1997) Resistance to the antitumor agent gallium nitrate in human leukemic cells is associated with decreased gallium/iron uptake, increased activity of iron regulatory protein-1, and decreased ferritin production. J Biol Chem 272:12151–12157

    Article  CAS  PubMed  Google Scholar 

  • Chitambar CR, Zivkovic Z (1987) Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. Can Res 47:3929–3934

    CAS  Google Scholar 

  • Chitambar CR, Zivkovic-Gilgenbach Z, Narasimhan J, Antholine WE (1990) Development of drug resistance to gallium nitrate through modulation of cellular iron uptake. J Biol Chem 50:4468–4472

    CAS  Google Scholar 

  • Conklin KA (2004) Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3:294–300. doi:10.1177/1534735404270335

    Article  CAS  PubMed  Google Scholar 

  • Cornwell MM, Pastan I, Gottesman MM (1987) Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262:2166–2170

    CAS  PubMed  Google Scholar 

  • Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML (2006) The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 121:144–158

    Article  CAS  PubMed  Google Scholar 

  • Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA et al (2012) The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochem Biophys Acta 1820:291–317. doi:10.1016/j.bbagen.2011.07.016

    Article  CAS  PubMed  Google Scholar 

  • Davies RJ, Faucher M, Racaniello LK, Carruthers A, Czech MP (1987) Insulin-like growth hormone factor I and epidermal growth factor regulate the expression of transferin receptors at the cell surface by distinct mechanisms. J Biol Chem 262:13126–13134

    Google Scholar 

  • Davies NP, Rahmanto YS, Chitambar CR, Richardson DR (2006) Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J Pharmacol Exp Ther 317:153–162

    Article  CAS  PubMed  Google Scholar 

  • Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060–1072. doi:10.1016/j.cell.2012.03.042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Epsztejn S, Glickstein H, Picard V, Slotki IN, Breuer W, Beaumont C, Cabantchik ZI (1999) H-Ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties. Blood 94:3593–3603

    CAS  PubMed  Google Scholar 

  • Fang D, Bao Y, Li X, Liu F, Cai K, Gao J, Liao Q (2010) Effects of iron deprivation on multidrug resistance of leukemic K562 cells. Chemotherapy 56:9–16. doi:10.1159/000287352

    Article  CAS  PubMed  Google Scholar 

  • Fritzer M, Barabas K, Szüts V, Berczi A, Szekeres T, Faulk WP, Goldenberg H (1992) Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells. Int J Cancer 52:619–623

    Article  CAS  PubMed  Google Scholar 

  • Fritzer M, Szekeres T, Szüts V, Jarayam HN, Goldenberg H (1996) Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells. Biochem Pharmacol 51:489–493

    Article  CAS  PubMed  Google Scholar 

  • Fukushima T, Kawabata H, Nakamura T, Iwao H, Nakajima A, Miki M et al (2011) Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res 31:1741–1744

    PubMed  Google Scholar 

  • Ganguly A, Basu S, Chakraborty P, Chatterjee S, Sarkar A, Chatterjee M, Choudhuri SK (2010) Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate. PLoS ONE. doi:10.1371/journal.pone.0011253

    Google Scholar 

  • Ganguly A, Chakraborty P, Banerjee K, Chatterjee S, Basu S, Sarkar A et al (2012) Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Biometals 25:149–163. doi:10.1007/s10534-011-9493-7

    Article  CAS  PubMed  Google Scholar 

  • Ganz T (2003) Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102:783–788

    Article  CAS  PubMed  Google Scholar 

  • Goswami T, Andrews NC (2006) Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 281:28494–28498

    Article  CAS  PubMed  Google Scholar 

  • Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR et al (2010) Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 119:283–293. doi:10.1007/s10549-009-0345-x

    Article  CAS  PubMed  Google Scholar 

  • Harris WR, Pecoraro VL (1983) Thermodynamic binding constants for gallium transferrin. Biochemistry 22:292–299

    Article  CAS  PubMed  Google Scholar 

  • Hatano T, Okhawa K, Matsuda M (1993) Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro. Tumor Biol 14:288–294

    Article  CAS  Google Scholar 

  • Head JF, Wang FEN, Elliott RL (1997) Antineoplastic drugs that interfere with iron metabolism in cancer. Adv Enzyme Regul 37:147–169

    Article  CAS  PubMed  Google Scholar 

  • Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117:285–297

    Article  CAS  PubMed  Google Scholar 

  • Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S (2014) Drug resistance in cancer: an overview. Cancers 6:1769–1792. doi:10.3390/cancers6031769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iseri OD, Kars MD, Gündüz U (2012) Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern. Mol Biol Rep 39:3505–3516. doi:10.1007/s11033-011-1123-5

    Article  CAS  PubMed  Google Scholar 

  • Kang HC (2004) Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10:272–284

    Article  CAS  PubMed  Google Scholar 

  • Kim DS, Na YJ, Kang MH, Yoon S, Choi CW (2016) Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. Korean J Intern Med 31:357–366

    Article  PubMed  PubMed Central  Google Scholar 

  • Klayman DL (1985) Qinghaosu (Artemisinin): an antimalarial drug from China. Science 228:1049–1055

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H (2007) Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm 329:94–102

    Article  CAS  PubMed  Google Scholar 

  • Koorts M, Viljoen M (2007) Ferritin and ferritin isoforms I: structure-function relationships, synthesis, degradation and secretion. Arch Physiol Biochem 113:30–54

    Article  CAS  PubMed  Google Scholar 

  • Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265–283

    Article  CAS  PubMed  Google Scholar 

  • Krishnamurthy P, Xie T, Schuetz JD (2007) The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther 114:345–358

    Article  CAS  PubMed  Google Scholar 

  • Lage H (2003) Drug resistance in breast cancer. Cancer Ther 1:81–91

    Google Scholar 

  • Lai BT, Gao JP, Lanks KW (1998) Mechanism of action and spectrum of cell lines sensitive to a doxorubicin-transferrin conjugate. Cancer Chemother Pharmacol 41:155–160

    Article  CAS  PubMed  Google Scholar 

  • Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L (2008) Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLoS ONE 3:1–10. doi:10.1371/journal.pone.0002303

    Article  Google Scholar 

  • Larson SM, Rasey JS, Allen DR, Nelson NJ, Grunbaum Z, Harp GD, Williams DL (1980) Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst 64:41–53

    CAS  PubMed  Google Scholar 

  • Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE (2007) Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67(3878):87

    Google Scholar 

  • Lee SY, Hille A, Kitanovic I, Jesse P, Henze G, Wölfl S et al (2011a) [FeIII(salophene)Cl], a potent iron salophene complex overcomes multiple drug resistance in lymphoma and leukemia cells. Leuk Res 35:387–393. doi:10.1016/j.leukres.2010.11.007

    Article  CAS  PubMed  Google Scholar 

  • Lee SY, Liu S, Mitchell RM, Slagle-Webb B, Hong YS, Sheehan JM, Connor JR (2011b) HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A. Int J Cancer 129:2104–2114. doi:10.1002/ijc.25888

    Article  CAS  PubMed  Google Scholar 

  • Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73

    Article  CAS  PubMed  Google Scholar 

  • Li H, Qian ZM (2002) Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 22:225–250

    Article  CAS  PubMed  Google Scholar 

  • Li Y, Shan F, Wu JM, Wu GS, Ding J, Xiao D, Yang WY, Atassi G, Léonce S, Caignard DH, Renard P (2001) Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg Med Chem Lett 11:5–8

    Article  PubMed  Google Scholar 

  • Li H, Sun H, Qian ZM (2002) The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci 23:206–209

    Article  CAS  PubMed  Google Scholar 

  • Li J, He K, Liu P, Xu LX (2016) Iron participated in breast cancer chemoresistance by reinforcing IL-6 paracrine loop. Biochem Biophys Res Commun 475:154–160. doi:10.1016/j.bbrc.2016.05.064

    Article  CAS  PubMed  Google Scholar 

  • Liu X, Madhankumar AB, Slagle-Webb B, Sheehan JM, Surguladze N, Connor JR (2011) Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. Can Res 71:2240–2249. doi:10.1158/0008-5472.CAN-10-1375

    Article  CAS  Google Scholar 

  • Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292

    Article  CAS  PubMed  Google Scholar 

  • Lubgan D, Jóźwiak Z, Grabenbauer GG, Distel LVR (2009) Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukemia cells. Cell Mol Biol Lett 14:113–127. doi:10.2478/s11658-008-0037-2

    Article  CAS  PubMed  Google Scholar 

  • Ma MZ, Chen G, Wang P, Lu WH, Zhu CF, Song M, Yang J, Wen S, Xu RH, Hu Y, Huang P (2015) Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Lett 368:88–96

    Article  CAS  PubMed  Google Scholar 

  • Madajewicz S, West CR, Park HC, Ghoorah J, Avellanosa AM, Takita H et al (1981) Phase II Study-Intra-arterial BCNU therapy for metastatic brain tumors. Cancer 47:653–657

    Article  CAS  PubMed  Google Scholar 

  • Narang VS, Pauletti GM, Gout PW, Buckley DJ, Buckley AR (2007) Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy 53:210–217. doi:10.1159/000100812

    Article  CAS  PubMed  Google Scholar 

  • Necker LM (1991) Regulation of transferin receptor expression and control of cell growth. Pathobiology 59:11–18

    Article  Google Scholar 

  • Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S (2002) Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 29:327–335

    Article  CAS  PubMed  Google Scholar 

  • Oliveira CC, Goossen B, Zanchin NIT, Mccarthy JEG, Hentze MW, Stripecke R (1993) Translational repression by the human iron-regulatory factor (IRF) in saccharomyces cerevisiae. Nucleic Acids Res 21:5316–5322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Olliaro PL, Haynes RK, Meunier B, Yuthavong Y (2001) Possible modes of action of the artemisinin-type compounds. Trends Parasitol 17:122–126

    Article  CAS  PubMed  Google Scholar 

  • Pierre JL, Fontecave M, Crichton RR (2002) Chemistry for an essential biological process: the reduction of ferric iron. Biometals 15:341–346

    Article  CAS  PubMed  Google Scholar 

  • Ponka P, Lok CN (1999) The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 31:1111–1137

    Article  CAS  PubMed  Google Scholar 

  • Qian ZM, Li H, Sun H, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561–587

    Article  CAS  PubMed  Google Scholar 

  • Rahbar AM, Fenselau C (2005) Unbiased examination of changes in plasma membrane proteins in drug resistant cancer cells. J Proteome Res 4:2148–2153

    Article  CAS  PubMed  Google Scholar 

  • Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB (2009) Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochem Biophys Acta 1790:702–717. doi:10.1016/j.bbagen.2008.04.003

    Article  CAS  PubMed  Google Scholar 

  • Roh JL, Kim EH, Jang HJ, Park JY, Shin D (2016) Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett 381:96–103. doi:10.1016/j.canlet.2016.07.035

    Article  CAS  PubMed  Google Scholar 

  • Roh JL, Kim EH, Jang H, Shin D (2017) Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol 11:254–262

    Article  CAS  PubMed  Google Scholar 

  • Sadava D, Phillips T, Lin C, Kane SE (2002) Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett 179:151–156

    Article  CAS  PubMed  Google Scholar 

  • Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2:373–383

    Article  CAS  PubMed  Google Scholar 

  • Sehm T, Fan Z, Ghoochani A, Rauh M, Engelhorn T, Minakaki G, Dorfler A, Klucken J, Buchfelder M, Eyupoglu IY, Savaskan N (2016) Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema. Oncotarget 7:36021–36033

    PubMed  PubMed Central  Google Scholar 

  • Sheth S (2014) Iron chelation: an update. Curr Opin Hematol 21:1–7. doi:10.1097/MOH.0000000000000031

    Article  Google Scholar 

  • Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA, Pogribny IP (2011) Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 126:63–71. doi:10.1007/s10549-010-0849-4

    Article  CAS  PubMed  Google Scholar 

  • Simon SM, Schindler M (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91:3497–3504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun X, Niu X, Chen R, He W, Chen D, Kang R, Tang D (2016) Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64:488–500. doi:10.1002/hep.28574

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Suzuki S, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y (1997) Modulation of doxorubicin resistance in a doxorubicin- resistant human leukaemia cell by an immunoliposome targeting transferring receptor. Br J Cancer 76:83–89

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tomaru A, Morimoto N, Morishita M, Takayama K, Fujita T, Maeda K, Kusuhara H, Sugiyama Y (2013) Studies on the intestinal absorption characteristics of sulfasalazine, a breast cancer resistance protein (BCRP) substrate. Drug Metab Pharmacokinetic 28:71–74

    Article  CAS  Google Scholar 

  • Torti SV, Torti FM (2011) Ironing out cancer. Can Res 71:1511–1514. doi:10.1158/0008-5472.CAN-10-3614

    Article  CAS  Google Scholar 

  • Torti SV, Torti FM (2013a) Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog 18:435–448

    Article  PubMed  PubMed Central  Google Scholar 

  • Torti SV, Torti FM (2013b) Iron and cancer: more ore to be mined. Nat Rev Cancer 13:342–355. doi:10.1038/nrc3495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Uchida M, Kang S, Reichhardt C, Harlen K, Douglas T (2010) The ferritin superfamily: supramolecular templates for materials synthesis. Biochem Biophys Acta 1800:834–845. doi:10.1016/j.bbagen.2009.12.00

    Article  CAS  PubMed  Google Scholar 

  • Van der Heijden J, de Jong MC, Dijkmans BAC, Lems WF, Oerlemans R, Kathmann I, Schalkwijk CG, Scheffer GL, Scheper RJ, Jansen G (2004) Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFa. Ann Rheum Dis 63:138–143. doi:10.1136/ard.2002.005249

    Article  PubMed  PubMed Central  Google Scholar 

  • Watts RN, Hawkins C, Ponka P, Richardson DR (2006) Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc Natl Acad Sci USA 103:7670–7675

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Whitnall M, Howard J, Ponka P, Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103:14901–14906

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, Lee RJ (2007) Reversal of multidrug resistance by transferrin conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci 10:350–357

    CAS  PubMed  Google Scholar 

  • Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X et al (2016) Ferroptosis: process and function. Cell Death Differ 23:369–379. doi:10.1038/cdd.2015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yalovenko TM, Todor IM, Lukianova NY, Chekhun VF (2016) Hepcidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs. Exp Oncol 38:84–88

    CAS  PubMed  Google Scholar 

  • Yang DI, Chen SD, Yang YT, Ju TC, Xu JM, Hsu CY (2004) Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1. Br J Pharmacol 141:988–996. doi:10.1038/sj.bjp.0705687

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, Zeh HJ, Kang R, Tang D (2015) The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol 2:e1054549. doi:10.1080/23723556.2015.1054549

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, Middle East Technical University, Universiteler Mah. Dumlupinar Blv. No:1, 06800, Cankaya, Ankara, Turkey

    Hasan Huseyin Kazan, Cagri Urfali-Mamatoglu & Ufuk Gunduz

Authors
  1. Hasan Huseyin Kazan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cagri Urfali-Mamatoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ufuk Gunduz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hasan Huseyin Kazan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kazan, H.H., Urfali-Mamatoglu, C. & Gunduz, U. Iron metabolism and drug resistance in cancer. Biometals 30, 629–641 (2017). https://doi.org/10.1007/s10534-017-0037-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10534-017-0037-7

Keywords

Search

Navigation